MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on August 14, 2006; DOI: 10.1124/mol.106.025759


0026-895X/06/7005-1812-1821$20.00
Mol Pharmacol 70:1812-1821, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.025759v1
70/5/1812    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ciucci, A.
Right arrow Articles by Santoro, M. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ciucci, A.
Right arrow Articles by Santoro, M. G.

Induction of Apoptosis in Estrogen Receptor-Negative Breast Cancer Cells by Natural and Synthetic Cyclopentenones: Role of the I{kappa}B Kinase/Nuclear Factor-{kappa}B Pathway

Alessandra Ciucci, Patrizia Gianferretti, Roberto Piva1, Thierry Guyot2, Timothy J. Snape, Stanley M. Roberts, and M. Gabriella Santoro

Department of Biology, University of Rome, Rome, Italy (A.C., P.G., R.P., M.G.S.); Department of Chemistry, University of Liverpool, Liverpool, United Kingdom (T.G.); and School of Chemistry, University of Manchester, Manchester, United Kingdom (T.J.S., S.M.R.)

Nuclear factor-{kappa}B (NF-{kappa}B), a transcription factor with a critical role in promoting inflammation and cell survival, is constitutively activated in estrogen-receptor (ER)-negative breast cancer and is considered a potential therapeutic target for this type of neoplasia. We have previously demonstrated that cyclopentenone prostaglandins are potent inhibitors of NF-{kappa}B activation by inflammatory cytokines, mitogens, and viral infection, via direct binding and modification of the beta subunit of the I{kappa}B kinase complex (IKK). Herein, we describe the NF-{kappa}B-dependent anticancer activity of natural and synthetic cyclopentenone IKK inhibitors. We demonstrate that the natural cyclopentenone 15-deoxy-{Delta}12,14prostaglandin J2 (15d-PGJ2) is a potent inhibitor of constitutive I{kappa}B-kinase and NF-{kappa}B activities in chemotherapy-resistant ER-negative breast cancer cells. 15d-PGJ2-induced inhibition of NF-{kappa}B function is rapidly followed by down-regulation of NF-{kappa}B-dependent antiapoptotic proteins cIAPs 1/2, Bcl-XL, and cellular FLICE-inhibitory protein, leading to caspase activation and induction of apoptosis in breast cancer cells resistant to treatment with paclitaxel and doxorubicin. We then demonstrate that the cyclopentenone ring structure is responsible for these activities, and we identify a new synthetic cyclopentenone derivative, 3-tert-butyldimethylsilyloxy-5-(E)-iso-propylmethylenecyclopent-2-enone (CTC-35), as a potent NF-{kappa}B inhibitor with proapoptotic activity in ER-negative breast cancer cells. The results open new perspectives in the search for novel proapoptotic molecules effective in the treatment of cancers presenting aberrant NF-{kappa}B regulation.


Received April 14, 2006; accepted August 14, 2006

Address correspondence to: Dr. M. Gabriella Santoro, Department of Biology, University of Rome Tor Vergata, Via della Ricerca Scientifica, 00133 Rome, Italy. E-mail: santoro{at}bio.uniroma2.it




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
J. O. Ban, J. H. Oh, B. Y. Hwang, D. C. Moon, H.-S. Jeong, S. Lee, S. Kim, H. Lee, K.-B. Kim, S. B. Han, et al.
Inflexinol inhibits colon cancer cell growth through inhibition of nuclear factor-{kappa}B activity via direct interaction with p50
Mol. Cancer Ther., June 1, 2009; 8(6): 1613 - 1624.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. L. Bissonnette, J. E. Teague, D. H. Sherr, and J. J. Schlezinger
An Endogenous Prostaglandin Enhances Environmental Phthalate-Induced Apoptosis in Bone Marrow B Cells: Activation of Distinct but Overlapping Pathways
J. Immunol., August 1, 2008; 181(3): 1728 - 1736.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. Singh, Q. Shi, S. T. Bailey, M. J. Palczewski, A. B. Pardee, J. D. Iglehart, and D. K. Biswas
Nuclear factor-{kappa}B activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer
Mol. Cancer Ther., July 1, 2007; 6(7): 1973 - 1982.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics